# First Interim Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huilai Zhang,¹ Ying Cheng,² Haiyan Yang,³ Liling Zhang,⁴ Liqun Zou,⁵ Ye Guo,⁶ Junning Cao,⁷ Huiqiang Huang,⁶ Zhao Wang,⁶ Sha Huang,⁰ Zhiyu Liang,⁰ Jiaoyan Lyu,⁰ Yiqian Fang,⁰ Aileen Cohen,⁰ Keshu Zhou¹¹


¹Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; ⁴Union Hospital, School of Medicine, Tongji University, Shanghai, China; ⁵Nanghai, China; ⁵Nanghai, China; ⁵Shanghai East Hospital, Sichuan University of Science and Technology, Wuhan, China; ⁴Union Hospital of Tongji Medicine, Tongji University, Shanghai, China; ⁵Shanghai, China; ⁴Union Hospital, School of Medicine, Tongji University, Shanghai, China; ⁵Shanghai, China; ⁴Union Hospital, Capital Medical University, Shanghai, China; ⁴Shanghai, China; ⁴Union Hospital of Zhengzhou, China; ⁴Union Hospital, Ch

# BACKGROUND

- Outcomes in patients with diffuse large B-cell lymphoma (DLBCL) have improved with recent advancements in treatment; however, relapsed/refractory (R/R) disease, which approximately one-third of patients will develop, remains a major cause of mortality<sup>1</sup>
- Effective therapies for R/R DLBCL are limited in China, especially for patients ineligible for high-dose therapy/ stem cell transplant (HDT/SCT)<sup>2</sup>
- Preclinical data suggest synergy of lenalidomide with zanubrutinib, a potent and selective Bruton tyrosine kinase inhibitor approved for various B-cell malignancies<sup>3,4</sup>
- Preliminary results for part 1 of this ongoing phase 1, open-label, dose-escalation/expansion study of zanubrutinib plus lenalidomide in Chinese patients with R/R DLBCL (BGB-3111-110; NCT04436107) were previously presented, detailing the recommended dose for expansion<sup>5</sup>
- Here, we present interim analysis results of BGB-3111-110

### METHODS

Figure 1. BGB-3111-110 Study Design



BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; HDT/SCT, high-dose therapy/stem cell transplant; QD, once daily; RP2D, recommended part 2 dose.

# RESULTS

#### **Patients**

- As of November 8, 2022, a total of 46 patients were treated and included in this interim analysis (27 in part 1; 19 in part 2; 30 at the recommended part 2 dose [RP2D])
- Median age was 60 years (range, 29-82 years); 82.6% had stage III-IV disease, 37.0% had refractory disease, and 69.6% had non-germinal center B-cell (non-GCB) disease
- The median number of prior systemic therapies was 1 (range, 1-5)
- Baseline characteristics are summarized in Table 1
- Median treatment exposure was 3.9 months (range, 0.4-24.9 months) for zanubrutinib and lenalidomide, and the median follow-up was 6.6 months (range, 0.5-25.5 months)


ambias and Dasalina Diagona Chara

	Part 1 Zanubrutinib 160 mg BID			Part 2 Zanubrutinib 160 mg BID		
Characteristics, n (%)	Lenalidomide 15 mg QD (dose level 1) (n=6)	Lenalidomide 20 mg QD (dose level 2) (n=10)	Lenalidomide 25 mg QD (dose level 3; RP2D) (n=11)	Lenalidomide 25 mg QD (RP2D) (n=19)	RP2D combined (n=30)	Total (N=46)
Sex	(11 0)	(11 10)	\ <i>\</i>	(11 15)	(11 33)	(11 10)
Male	4 (66.7)	6 (60.0)	5 (45.5)	9 (47.4)	14 (46.7)	24 (52.2)
Female	2 (33.3)	4 (40.0)	6 (54.5)	10 (52.6)	16 (53.3)	22 (47.8)
Age	_ (55.5)	. (1333)	- (	()	(,	(,
Median (range), years	51.5 (29-65)	57.0 (31-77)	60.0 (32-77)	61.0 (42-82)	61.0 (32-82)	60.0 (29-82)
>60 years	1 (16.7)	2 (20.0)	5 (45.5)	12 (63.2)	17 (56.7)	20 (43.5)
ECOG PS	, /	,,	,,	()	()	( /
0	3 (50.0)	4 (40.0)	3 (27.3)	6 (31.6)	9 (30.0)	16 (34.8)
1	3 (50.0)	6 (60.0)	7 (63.6)	12 (63.2)	19 (63.3)	28 (60.9)
2	0	0	1 (9.1)	1 (5.3)	2 (6.7)	2 (4.3)
Disease stage at study entry			, ,		, ,	
Stage I	1 (16.7)	0	0	0	0	1 (2.2)
Stage II	0	2 (20.0)	4 (36.4)	1 (5.3)	5 (16.7)	7 (15.2)
Stage II bulky	0	0	0	0	0	0
Stage III	0	3 (30.0)	3 (27.3)	7 (36.8)	10 (33.3)	13 (28.3)
Stage IV	5 (83.3)	5 (50.0)	4 (36.4)	11 (57.9)	15 (50.0)	25 (54.3)
Number of prior systemic the	rapies					
1	3 (50.0)	6 (60.0)	6 (54.5)	12 (63.2)	18 (60.0)	27 (58.7)
2	3 (50.0)	4 (40.0)	2 (18.2)	4 (21.1)	6 (20.0)	13 (28.3)
≥3	0	0	3 (27.3)	3 (15.8)	6 (20.0)	6 (13.0)
Disease status						
Refractory	4 (66.7)	7 (70.0)	3 (27.3)	3 (15.8)	6 (20.0)	17 (37.0)
Relapsed	2 (33.3)	3 (30.0)	8 (72.7)	16 (84.2)	24 (80.0)	29 (63.0)
DLBCL subtype						
GCB	3 (50.0)	3 (30.0)	3 (27.3)	3 (15.8)	6 (20.0)	12 (26.1)
Non-GCB	3 (50.0)	6 (60.0)	8 (72.7)	15 (78.9)	23 (76.7)	32 (69.6)
Unknown	0	1 (10.0)	0	1 (5.3)	1 (3.3)	2 (4.3)
Prior radiotherapy	1 (16.7)	2 (20.0)	3 (27.3)	2 (10.5)	5 (16.7)	8 (17.4)
Prior transplant	0	0	0	0	0	0

BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B-cell; non-GCB, non-germinal center B-cell; QD, once daily; RP2D, recommended part 2 dos


- The overall response rate (ORR) was 45.7% overall (95% CI, 30.9%-61.0%; complete response [CR] rate, 23.9%) (Figure 2)
- At RP2D, the ORR was 56.7% (95% CI, 37.4%-74.5%; CR, 30.0%) in all patients
- At RP2D, the ORR was 60.9% (95% CI, 38.5%-80.3%; CR, 34.8%) in patients with non-GCB disease and 50.0% (95% CI, 11.8%-88.2%; CR, 16.7%) in patients with GCB disease (**Figure 3**)
- Overall, the median duration of response (DOR) was not reached, and the 6-month event-free rate was 63.5% (95% CI, 32.8%-83.0%) (**Figures 4-6**)
- At data cutoff, 16 of the 21 responders were still progression free, with the longest progression-free survival (PFS) of >20.8 months observed in a patient receiving dose level 1 (Figure 4)
- At RP2D, DOR was not reached, and the 6-month event-free rate was 59.4% (95% CI, 23.8%-82.8%)
- Overall, median PFS was 5.5 months (95% CI, 2.8-8.3 months), with a 9-month event-free rate of 31.1% (95% CI, 16.4%-47.0%) (**Figures 7** and **8**)
- At RP2D, the median PFS was 5.5 months (95% CI, 2.8 months-not evaluable [NE]), with a 9-month eventfree rate of 37.4% (95% CI, 17.6%-57.4%)

Figure 2. Disease Response by Investigator Based on the Lugano 2014<sup>6</sup> Classification




DIS, discontinued prior to first treatment; NE, not evaluable; RP2D, recommended part 2 dose. Overall response is defined as achieving at least a best overall response of PR or better. <sup>b</sup> Two-sided Clopper-Pearson 95% CI.

Figure 3. Disease Response by Subtype




DIS, discontinued prior to first assessment; NE, not evaluable; RP2D, recommended part 2 dose Overall response is defined as achieving at least a best overall response of PR or better. <sup>b</sup> Two-sided Clopper-Pearson 95% CI.

Figure 4. Swimlane Plot of Treatment Duration With Response per Overall Assessment by Investigator



BID, twice daily; NE, not evaluable; QD, once daily; RP2D, recommended part 2 dose

#### Figure 5. DOR by Investigator Based on the Lugano 2014<sup>6</sup> Classification






Figure 6. Kaplan-Meier Estimate of DOR by Investigator Based on the Lugano 2014<sup>6</sup> Classification





Figure 7. PFS by Investigator Based on the Lugano 2014<sup>6</sup> Classification

PFS, progression-free survival; RP2D, recommended part 2 dose

NE, not evaluable; RP2D, recommended part 2 dose

RP2D, recommended part 2 dose


	Median PFS follow-up, months <sup>a</sup>		PFS, months <sup>b</sup>			
					Median (95% CI)	Range
Part 1, dose level 1 (n=6	,		20.80	Part 1, dose level 1 (n=6)	2.79 (0.43-NE)	0.03+ to 20.80+
Part 1, dose level 2 (n=10)	,	11.10		Part 1, dose level 2 (n=10)	2.89 (2.69-NE)	2.69 to 14.72+
art 1, dose level 3/RP2D (n=11	,	8.34		Part 1, dose level 3/RP2D (n=11)	NE (5.49-NE)	2.83+ to 11.43+
Part 2/RP2D (n=19)	2.99	_		Part 2/RP2D (n=19)	2.79 (2.53-NE)	0.03+ to 5.62+
RP2D combined (n=30)	)	8.25			,	
Total (N=46	)	8.34		RP2D combined (n=30)	5.52 (2.79-NE)	0.03+ to 11.43+
	,			Total (N=46)	5.49 (2.79-8.28)	0.03+ to 20.80+



RP2D combined (n=30) All patients (N=46) PFS is defined as the time from start of study treatment to PD or death of any cause, whichever occurs firs

Median follow-up time is estimated by the reverse Kaplan-Meier method. b Medians were estimated by Kaplan-Meier method, with 95% CIs estimated using the Brookmeyer and Crowley method. Event-free rates were estimated by Kaplan-Meier method, with 95% CIs estimated using the Brookmeyer and Crowley method.

Figure 8. Kaplan-Meier Estimate of PFS by Investigator Based on the Lugano 2014<sup>6</sup> Classification



# CONCLUSIONS

- The zanubrutinib 160 mg twice daily plus lenalidomide 25 mg once daily combination demonstrated an acceptable safety profile and promising efficacy in patients with R/R DLBCL
- Further evaluation of the combination in a larger sample is planned in future analyses

#### Safety

- All 46 patients experienced ≥1 treatment-emergent adverse event (TEAE) (**Table 2**)
- Grade ≥3 TEAEs occurred in 60.9% of patients, were most commonly hematologic toxicities, and were generally manageable across all dose levels (**Table 3**)
- At RP2D, grade ≥3 TEAEs occurred in 60.0% of patients, most commonly neutrophil count decreased (43.3%), white blood cell count decreased (23.3%), and pneumonia (13.3%); 1 patient (3.3%) had febrile neutropenia (grade 3) but recovered within 2 days
- Four patients (8.7%) experienced TEAEs leading to treatment discontinuation
- Two patients discontinued both zanubrutinib and lenalidomide (grade 5 cardiopulmonary failure unrelated to study treatment [part 1, dose level 2], grade 3 pulmonary embolism related to lenalidomide [part 1, dose level 3/RP2D])
- Two patients discontinued lenalidomide (grade 3 platelet count decreased related to both drugs [part 1, dose level 2], grade 1 rash related to both drugs [part 2, RP2D])
- Two TEAEs (cardiopulmonary failure, pneumonia) leading to death were reported; both were unrelated to

Table 2. TEAEs

		Part 1 Zanubrutinib 160 mg BID		Part 2 Zanubrutinib 160 mg BID		
Preferred term, n (%)	Lenalidomide 15 mg QD (dose level 1) (n=6)	Lenalidomide 20 mg QD (dose level 2) (n=10)	Lenalidomide 25 mg QD (dose level 3; RP2D) (n=11)	Lenalidomide 25 mg QD (RP2D) (n=19)	RP2D combined (n=30)	Total (N=46)
Patients with ≥1 TEAE <sup>a</sup>	6 (100.0)	10 (100.0)	11 (100.0)	19 (100.0)	30 (100.0)	46 (100.0)
Neutrophil count decreased	2 (33.3)	6 (60.0)	10 (90.9)	14 (73.7)	24 (80.0)	32 (69.6)
White blood cell count decreased	3 (50.0)	6 (60.0)	9 (81.8)	13 (68.4)	22 (73.3)	31 (67.4)
Platelet count decreased	1 (16.7)	7 (70.0)	7 (63.6)	8 (42.1)	15 (50.0)	23 (50.0)
Anemia	2 (33.3)	5 (50.0)	7 (63.6)	5 (26.3)	12 (40.0)	19 (41.3)
Lymphocyte count decreased	4 (66.7)	5 (50.0)	5 (45.5)	2 (10.5)	7 (23.3)	16 (34.8)
Hypokalemia	2 (33.3)	3 (30.0)	4 (36.4)	6 (31.6)	10 (33.3)	15 (32.6)
ALT increased	0	2 (20.0)	5 (45.5)	7 (36.8)	12 (40.0)	14 (30.4)
AST increased	0	4 (40.0)	5 (45.5)	5 (26.3)	10 (33.3)	14 (30.4)
Rash	2 (33.3)	4 (40.0)	2 (18.2)	5 (26.3)	7 (23.3)	13 (28.3)
γ-Glutamyltransferase increased	1 (16.7)	1 (10.0)	4 (36.4)	6 (31.6)	10 (33.3)	12 (26.1)
Hypoalbuminemia	1 (16.7)	4 (40.0)	3 (27.3)	2 (10.5)	5 (16.7)	10 (21.7)
Pneumonia	0	2 (20.0)	4 (36.4)	4 (21.1)	8 (26.7)	10 (21.7)
Serious	0	3 (30.0)	3 (27.3)	5 (26.3)	8 (26.7)	11 (23.9)
Leading to death	0	1 (10.0)	0	1 (5.3)	1 (3.3)	2 (4.3)
Leading to treatment discontinuation	0	2 (20.0)	1 (9.1)	1 (5.3)	2 (6.7)	4 (8.7)
Leading to dose modification	3 (50.0)	6 (60.0)	7 (63.6)	10 (52.6)	17 (56.7)	26 (56.5)
Leading to dose interruption	3 (50.0)	6 (60.0)	6 (54.5)	8 (42.1)	14 (46.7)	23 (50.0)
Leading to dose reduction	0	0	3 (27.3)	2 (10.5)	5 (16.7)	5 (10.9)
ALT claning aminetransferage ACT concretes aminetrar	reference RID twice deily OD once deil	VI DD2D recommended port 2 dece		-		

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; QD, once daily; RP2D, recommended part 2 dose. TEAEs are defined as adverse events that had an onset date on or after the date of first dose of study drug up to 30 days after the last dose of zanubrutinib or lenalidomide (whichever comes later) or to the start of new anticancer therapy, whichever comes first. Any-grade TEAEs occurring in ≥20% of patients are shown

Table 2 Crede >2 TEAE

		Part 2 Zanubrutinib 160 mg BID				
Preferred term, n (%)	Lenalidomide 15 mg QD (dose level 1) (n=6)	Lenalidomide 20 mg QD (dose level 2) (n=10)	Lenalidomide 25 mg QD (dose level 3; RP2D) (n=11)	Lenalidomide 25 mg QD (RP2D) (n=19)	RP2D combined (n=30)	Total (N=46)
Grade ≥3 TEAEsª	4 (66.7)	6 (60.0)	8 (72.7)	10 (52.6)	18 (60.0)	28 (60.9)
Neutrophil count decreased	2 (33.3)	6 (60.0)	6 (54.5)	7 (36.8)	13 (43.3)	21 (45.7)
White blood cell count decreased	0	4 (40.0)	4 (36.4)	3 (15.8)	7 (23.3)	11 (23.9)
Lymphocyte count decreased	2 (33.3)	1 (10.0)	1 (9.1)	1 (5.3)	2 (6.7)	5 (10.9)
Pneumonia	0	1 (10.0)	1 (9.1)	3 (15.8)	4 (13.3)	5 (10.9)
Platelet count decreased	0	2 (20.0)	2 (18.2)	0	2 (6.7)	4 (8.7)
Anemia	0	2 (20.0)	0	1 (5.3)	1 (3.3)	3 (6.5)
Hypokalemia	0	0	2 (18.2)	1 (5.3)	3 (10.0)	3 (6.5)
Neutropenia	0	0	2 (18.2)	0	2 (6.7)	2 (4.3)

TEAEs are defined as adverse events that had an onset date on or after the date of the first dose of study drug up to 30 days after the last dose of zanubrutinib or lenalidomide (whichever comes later) or to the start of new anticancer therapy, whichever comes first. Grade ≥3 TEAEs occurring in >1 patient are shown.

#### REFERENCES

1. Poletto S. et al. Cancer Treat Rev. 2022:110:102443. 2. Zhu J. et al. *Chin J Cancer Res.* 2021:33(3):289-301. Brukinsa (zanubrutinib). Prescribing information. BeiGene USA, Inc; 2023. 4. Yang Y, et al. Cancer Cell. 2012;21(6):723-737

5. Zhang H, et al. Presented at: American Society of Hematology Annual Meeting; December 10-13, 2022; New Orleans, LA. Abstract 1627. 6. Cheson BD, et al. J Clin Oncol. 2014;32(27):3059-3068

### **DISCLOSURES** YG: honoraria from Merck Serono, Roche, MSD, and BMS and board of

directors or advisory committee membership for Merck Serono MSD Bayer, Roche, and GSK. SH, ZL, JL, YF, AC: employment and stock with BeiGene. HZ, YC, HY, LZ, LZ, JC, HH, ZW, KZ: nothing to disclose.

# CORRESPONDENCE

Huilai Zhang, MD, PhD Tianjin Medical University Center Institute & Hospita Tianjin, China hlwgq@126.com

of the participating centers. This study was sponsored by BeiGene Co, Ltd. Medical writing and editorial assistance were provided, under the direction of authors, by Mary Ann Honors, PhD, MPH (Articulate Science, LLC), and was supported by BeiGene.

> Copies of this presentation obtained through Quick Response (QI code are for personal use only and may not be reproduced witho permission from EHA and the authors of this presentatio

